Binding of the human immunodeficiency virus (HIV) envelope gp120 glycoprotein to CD4 and CCR5 receptors on the plasma membrane initiates the viral entry process. Although plasma membrane cholesterol plays an important role in HIV entry, its modulating effect on the viral entry process is unclear. Using fluorescence resonance energy transfer imaging, we have provided evidence here that CD4 and CCR5 localize in different microenvironments on the surface of resting cells. Binding of the third variable region V3-containing gp120 core to CD4 and CCR5 induced association between these receptors, which could be directly monitored by fluorescence resonance energy transfer on the plasma membrane of live cells. Depletion of cholesterol from the plasma membrane abolished the gp120 core-induced associations between CD4 and CCR5, and reloading cholesterol restored the associations in live cells. Our studies suggest that, during the first step of the HIV entry process, gp120 binding alters the microenvironments of unbound CD4 and CCR5, with plasma membrane cholesterol required for the formation of the HIV entry complex.

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M607302200DOI Listing

Publication Analysis

Top Keywords

cd4 ccr5
24
plasma membrane
20
fluorescence resonance
12
resonance energy
12
energy transfer
12
entry process
12
hiv entry
12
transfer imaging
8
viral entry
8
membrane cholesterol
8

Similar Publications

People living with HIV (PLWH) experience HIV-associated neurocognitive disorders (HAND), even though combination antiretroviral therapy (cART) suppresses HIV replication. HIV-1 transactivator of transcription (HIV-1 Tat) contributes to the development of HAND through neuroinflammatory and neurotoxic mechanisms. C-C chemokine 5 receptor (CCR5) is important in immune cell targeting and is a co-receptor for HIV viral entry into CD4+ cells.

View Article and Find Full Text PDF

Two Disaccharide-Bearing Polyethers, K-41B and K-41Bm, Potently Inhibit HIV-1 via Mechanisms Different from That of Their Precursor Polyether, K-41A.

Curr Issues Mol Biol

November 2024

Guangxi Key Laboratory of AIDS Prevention and Treatment, School of Public Health, Guangxi Medical University, Nanning 530021, China.

The screening of novel antiviral agents from marine microorganisms is an important strategy for new drug development. Our previous study found that polyether K-41A and its analog K-41Am, derived from a marine Streptomyces strain, exhibit anti-HIV activity by suppressing the activities of HIV-1 reverse transcriptase (RT) and its integrase (IN). Among the K-41A derivatives, two disaccharide-bearing polyethers-K-41B and K-41Bm-were found to have potent anti-HIV-1 activity in vitro.

View Article and Find Full Text PDF

eCD4-immunoglobulin (Ig) is an HIV entry inhibitor that mimics the engagement of both CD4 and CCR5 with the HIV envelope (Env) protein, a property that imbues it with remarkable potency and breadth. However, env is exceptionally genetically malleable and can evolve to escape a wide variety of entry inhibitors. Here we document the evolution of partial eCD4-Ig resistance in SHIV-AD8-infected rhesus macaques (RMs) treated with adeno-associated virus vectors encoding eCD4-Ig.

View Article and Find Full Text PDF

Stronger binding affinities of in provide insights into HIV/host interactions.

Infect Dis Model

March 2025

Interdisciplinary Program in Bioinformatics, Seoul National University, Seoul, Republic of Korea.

Human immunodeficiency virus-1 (HIV-1) exploits the viral protein and host / receptors for the pandemic infection to humans. The host co-receptors of not only humans but also several primates and HIV-model mice can interact with the HIV receptor. However, the molecular mechanisms of these interactions remain unclear.

View Article and Find Full Text PDF
Article Synopsis
  • HSPC-based gene therapy shows potential for long-term HIV-1 remission after a single treatment, using a lentiviral vector to deliver three anti-HIV-1 genes.
  • Two of the genes focus on preventing infection by targeting the CCR5 co-receptor and inhibiting fusion of the virus, while the third gene is designed to attack infected cells.
  • The therapy was successful in humanized mouse models, significantly reducing HIV-1 viral load and allowing for safe removal of modified cells if necessary, demonstrating both effectiveness and safety of the approach.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!